Breaking Ground in Cancer Care: Intas Launches India’s First Immunotherapy for ES-SCLC 🇮🇳
Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), India’s first PD-1 inhibitor for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — marking a historic milestone in oncology care across the country.
🔹 First PD-1 inhibitor globally approved for ES-SCLC
🔹 Supported by the ASTRUM-005 trial – 40% reduction in risk of death
🔹 ESMO-MCBS score: 4/5 – highest clinical benefit in its class
🔹 Available at ~75% lower cost than other current immunotherapies in India
🔹 Licensed from Shanghai Henlius Biotech, currently approved in 40+ countries
What sets Serplulimab apart?
✅ Dual blockade of PD-L1 and PD-L2
✅ Deep immune engagement via highest PD-1 internalization
✅ Proven results in SCLC, NSCLC, ESCC, and MSI-high cancers
💬 Binish Chudgar, CMD of Intas Pharmaceuticals:
“This launch reflects our commitment to accelerating access to globally validated therapies in a cost-effective and timely manner.”
🎯 With HETRONIFLY™, Intas is not just strengthening its oncology portfolio—it’s transforming hope into action for cancer patients in India.
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
📢 Advertise with BioPatrika – Reach the Right Audience, Fast!
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
